Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response

Tamsulosin, sold under the brand name Flomax, is a commonly prescribed medication for benign prostatic hypertrophy (BPH). While generally well-tolerated, this medication can induce life-threatening tachyarrhythmias. Early recognition of this adverse effect can lead to prompt discontinuation of the t...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuire, Duncan, Ahdi, Heaveen, Mielke, Nicholas, Bahl, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261835/
https://www.ncbi.nlm.nih.gov/pubmed/35812583
http://dx.doi.org/10.7759/cureus.25714
_version_ 1784742366650826752
author McGuire, Duncan
Ahdi, Heaveen
Mielke, Nicholas
Bahl, Amit
author_facet McGuire, Duncan
Ahdi, Heaveen
Mielke, Nicholas
Bahl, Amit
author_sort McGuire, Duncan
collection PubMed
description Tamsulosin, sold under the brand name Flomax, is a commonly prescribed medication for benign prostatic hypertrophy (BPH). While generally well-tolerated, this medication can induce life-threatening tachyarrhythmias. Early recognition of this adverse effect can lead to prompt discontinuation of the therapy in an effort to reduce arrhythmia recurrence. Herein we describe a case of atrial fibrillation with rapid ventricular response in a male patient who started on tamsulosin two days prior.
format Online
Article
Text
id pubmed-9261835
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-92618352022-07-08 Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response McGuire, Duncan Ahdi, Heaveen Mielke, Nicholas Bahl, Amit Cureus Cardiology Tamsulosin, sold under the brand name Flomax, is a commonly prescribed medication for benign prostatic hypertrophy (BPH). While generally well-tolerated, this medication can induce life-threatening tachyarrhythmias. Early recognition of this adverse effect can lead to prompt discontinuation of the therapy in an effort to reduce arrhythmia recurrence. Herein we describe a case of atrial fibrillation with rapid ventricular response in a male patient who started on tamsulosin two days prior. Cureus 2022-06-07 /pmc/articles/PMC9261835/ /pubmed/35812583 http://dx.doi.org/10.7759/cureus.25714 Text en Copyright © 2022, McGuire et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
McGuire, Duncan
Ahdi, Heaveen
Mielke, Nicholas
Bahl, Amit
Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response
title Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response
title_full Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response
title_fullStr Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response
title_full_unstemmed Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response
title_short Tamsulosin-Induced Atrial Fibrillation With Rapid Ventricular Response
title_sort tamsulosin-induced atrial fibrillation with rapid ventricular response
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261835/
https://www.ncbi.nlm.nih.gov/pubmed/35812583
http://dx.doi.org/10.7759/cureus.25714
work_keys_str_mv AT mcguireduncan tamsulosininducedatrialfibrillationwithrapidventricularresponse
AT ahdiheaveen tamsulosininducedatrialfibrillationwithrapidventricularresponse
AT mielkenicholas tamsulosininducedatrialfibrillationwithrapidventricularresponse
AT bahlamit tamsulosininducedatrialfibrillationwithrapidventricularresponse

Ejemplares similares